Anti-tumor efficacy and preferential localization of KR12, <I>KRAS</I> mutation specific alkylating agent in <I>KRAS</I> mutant xenografts with little to no adverse effects

Takahiro Inoue; Kiriko Hiraoka; Hiroyuki Yoda; Takayoshi Watanabe; Atsushi Takatori; Nobuko Koshikawa; Shigeharu Wakana; Toshikazu Bando; Hiroshi Sugiyama; Toshinori Ozaki; Hiroki Nagase

4:45 PM - 6:45 PM

[3P1112] Anti-tumor efficacy and preferential localization of KR12, KRAS mutation specific alkylating agent in KRAS mutant xenografts with little to no adverse effects

〇Takahiro Inoue¹, Kiriko Hiraoka¹, Hiroyuki Yoda¹, Takayoshi Watanabe¹, Atsushi Takatori¹, Nobuko Koshikawa¹, Shigeharu Wakana³, Toshikazu Bando⁴, Hiroshi Sugiyama⁴, Toshinori Ozaki², Hiroki Nagase¹ (1.Lab. Cancer Genetics, Chiba Cancer Centr. Res. Inst., 2.Lab. DNA Damage Signaling, Chiba Cancer Centr Res. Inst., 3.Japan Mouse Clinic, RIKEN BRC, 4.Dep. Chem., Grad. Sch. Sci., Univ. Kyoto)

pyrrole-imidazole polyamide, KRAS, in vivo

This archive has moved to the member page of The Molecular Biology Society of Japan and The Japanese Biochemical Society.
Members of the either society can access the abstracts via links at the member page of the sites.
Please feel free to contact the journal offices for any inquiries.

BMB2015 Biochemistry and Molecular Biology

[3P1112] Anti-tumor efficacy and preferential localization of KR12, KRAS mutation specific alkylating agent in KRAS mutant xenografts with little to no adverse effects

Password